Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Añadir filtros








Intervalo de año
1.
Arch. endocrinol. metab. (Online) ; 65(2): 185-197, Mar.-Apr. 2021. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1248805

RESUMEN

ABSTRACT Objective: The main aim of the study was to evaluate the patients' glycemic control and adherence to self-care tasks. Materials and methods: Patients with type 1 diabetes mellitus (T1DM) or latent autoimmune diabetes of the adult (LADA) using a multiple daily injection (MDI) regimen with carbohydrate counting (n = 25, Subgroup B) or fixed insulin dose (n = 25, Subgroup C) were allocated to use the application (app) for 12 weeks. Both subgroups were compared with each other and against a control group (n = 25, Group A) comprising patients with T1DM or LADA treated with continuous subcutaneous insulin infusion (CSII) in a parallel-group, open-label, clinical treatment trial. All patients had glycated hemoglobin (A1C) levels measured and were asked to fill out the Diabetes Self-Management Profile (DSMP) questionnaire at study start and end. The patients were instructed to measure capillary glucose six times daily in study weeks 4, 8, and 12. Results: Mean A1C levels decreased 0.725% in Subgroup C in intragroup analysis (p = 0.0063), and had a mean variation of 0.834% compared with Group A (p = 0.003). Mean DSMP scores increased 5.77 points in Subgroup B in intragroup analysis (p = 0.0004) and increased by a mean of 6.815 points in relation to Group A (p = 0.002). Conclusion: OneTouch Reveal improved both A1C levels and DSMP scores in patients with T1DM or LADA compared with standard treatment (CSII).


Asunto(s)
Humanos , Adulto , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Aplicaciones Móviles , Autocuidado , Glucemia/análisis , Hemoglobina Glucada/análisis , Sistemas de Infusión de Insulina , Control Glucémico , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico
2.
Arch. endocrinol. metab. (Online) ; 59(5): 455-459, Oct. 2015. tab, graf
Artículo en Inglés | LILACS | ID: lil-764121

RESUMEN

Brown tumors are rare skeletal manifestations that occur in less than 2% of primary hyperparathyroidism (PHPT) cases. Even rarer is the occurrence of brown tumor of the orbit, and few cases have been reported around the world. The rare instance of this benign tumor has prompted us to report the case and treatment of an orbital brown tumor in a patient with PHPT caused by parathyroid adenoma. We present the case of a patient undergoing follow-up at a referral center. The 60-year-old female patient, presented herself with progressive swelling in the nasal region, epistaxis and proptosis, she had noticed seven months prior to our examination. Multiple imaging and laboratory findings revealed parathyroid hormone (PTH)-dependent hypercalcemia (total calcium = 14.3 mg/dL and PTH = 1,573 pg/mL), a nodular lesion in the upper pole of the left thyroid lobe and increased uptake in left upper cervical region. The patient underwent left superior parathyroidectomy in September 2011, which led to the normalization of hypercalcemia and regression of the orbital tumor, as seen on control CT scan. This case highlights the spontaneous regression of the brown tumor after surgical management of the parathyroid adenoma.


Asunto(s)
Femenino , Humanos , Persona de Mediana Edad , Adenoma/cirugía , Hiperparatiroidismo Primario/diagnóstico , Enfermedades Orbitales/patología , Neoplasias de las Paratiroides/cirugía , Adenoma , Densidad Ósea , Calcio/sangre , Enfermedades Orbitales , Paratiroidectomía , Neoplasias de las Paratiroides , Remisión Espontánea , Tomografía Computarizada por Rayos X
3.
Arq. bras. cardiol ; 102(5,supl.1): 1-41, 05/2014. tab
Artículo en Inglés | LILACS | ID: lil-709328
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA